PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 3, 20260 citations

Short- and mid-term outcomes of transanal/transperineal minimally invasive surgery for locally recurrent rectal cancer.

View Full Paper
YTY TsukadaSSS SasakiTMT Mori

Key Points

  • This research aims to compare the outcomes of transanal/transperineal minimally invasive surgery versus conventional methods in locally recurrent rectal cancer.
  • Retrospective observational study of 98 patients with locally recurrent rectal cancer from 2008 to 2022
  • Patients classified into transanal/transperineal minimally invasive surgery (34) and conventional surgery (64)
  • Comparison of perioperative and mid-term oncologic outcomes including operative time and blood loss
  • Transanal/transperineal surgery had a median resection time of 225 minutes compared to 252 minutes for conventional surgery (p = 0.0176)
  • Blood loss was significantly lower in transanal/transperineal surgery (median 420.5 mL) compared to conventional (median 1068 mL; p < 0.0001)
  • In three-year overall survival, transanal/transperineal surgery showed 89.7% compared to 77.7% for conventional, with p = 0.2271

Abstract

BACKGROUND: Surgical resection, the primary treatment for locally recurrent rectal cancer (LRRC), is technically challenging. Transanal/transperineal minimally invasive surgery (Ta/Tp MIS) improves visualization and access through undisturbed planes. This study compared the short- and mid-term outcomes of Ta/Tp MIS with those of conventional non-Ta/Tp MIS for LRRC. METHODS: This retrospective observational study involved 98 patients who underwent curative-intent surgery for LRRC at a single tertiary cancer center between April 2008 and March 2022. Patients were classified into Ta/Tp MIS (n = 34) and non-Ta/Tp MIS (n = 64) groups. Perioperative and mid-term oncologic outcomes were compared, including operative time, blood loss, intraoperative transfusion, postoperative complications, pathological R0 resection, recurrence-free survival, local recurrence, and overall survival. RESULTS: Ta/Tp MIS was associated with reductions in resection time (median, 225 versus 252 min; p = 0.0176), blood loss (median, 420.5 versus 1068 mL; p < 0.0001), and intraoperative transfusions (17.7% versus 48.4%, p = 0.0041), and tended toward a shorter operative time (median, 366.5 versus 418.5 min; p = 0.1170). R0 resection (91.2% versus 89.1%), postoperative complications (overall Clavien-Dindo complication grade: 76.5% versus 75.0%, p = 1; grade ≥ 3: 41.2% versus 37.5%, p = 0.8282), 3-year recurrence-free survival (46.3% versus 44.2%, p = 0.9079), local recurrence (24.8% versus 37.7%, p = 0.3130), and 3-year overall survival (89.7% versus 77.7%, p = 0.2271) were comparable between groups. CONCLUSIONS: Ta/Tp MIS appears to be a feasible surgical approach for selected patients with LRRC, and in this retrospective analysis, was associated with shorter resection time and reduced blood loss. No clear differences were observed in postoperative complications or short- to mid-term oncologic outcomes compared with conventional approaches.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Tsukada et al. (2026) studied this question.

synapsesocial.com/papers/69f6e6648071d4f1bdfc70d3https://doi.org/10.1007/s10151-026-03312-w
Ask AI
Helpful
Bookmark
Share
View Full Paper